CRx-102 is a synergistic combination drug candidate containing the cardiovascular drug
dipyridamole and a very low dose of the glucocorticoid prednisolone. CRx-102 is believed to
work through a novel mechanism of action in which dipyridamole selectively amplifies the
anti-inflammatory and immunomodulatory activities of the glucocorticoid without replicating
the dose-dependent adverse effects.
CRx-102 has been associated with clinical benefit in proof of concept studies in subjects
with hand OA and RA. This is the first study to explore the efficacy of CRx-102 in knee OA.
It is considered a dose-finding study and will also compare the potential benefits of CRx-102
treatment to both prednisolone administered alone and to placebo in this indication.